Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects

被引：2

作者：

Karaali, Ridvan ^{[1
]}

Dinc, Harika Oyku Oyku ^{[2
]}

Balkan, Ilker Inanc ^{[1
]}

Can, Gunay ^{[3
]}

Keskin, Elif ^{[4
]}

Colak, Hatice ^{[1
]}

Dasdemir, Ferhat Osman ^{[4
]}

Aydogan, Okan ^{[5
]}

Budak, Beyhan ^{[1
]}

Kaya, Sibel Yildiz ^{[1
]}

Kocazeybek, Bekir ^{[4
]}

Saltoglu, Nese ^{[1
]}

机构：

[1] Istanbul Univ Cerrahpasa, Dept Infect Dis & Clin Microbiol, Cerrahpasa Med Fac, Istanbul, Turkiye

[2] Bezmialem Vakif Univ Istanbul, Fac Pharm, Dept Pharmaceut Microbiol, Istanbul, Turkiye

[3] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Publ Hlth, Istanbul, Turkiye

[4] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Med Microbiol, Istanbul, Turkiye

[5] Istanbul Medipol Univ, Fac Med, Dept Med Microbiol, Istanbul, Turkiye

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2023年 / 107卷 / 02期

关键词：

Vaccine; Inactivated CoronaVac; BNT162b2; mRNA; Side effects; Neutralizing antibody; Vaccine schemes;

D O I：

10.1016/j.diagmicrobio.2023.116017

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Real-life data are needed regarding the appropriate time and selection of vaccination strategies, homologous or heterologous. We aimed to compare neutralizing antibody levels and side effects in different vaccination schemes. The study included 310 Health Care Workers (HCWs) vaccinated with 5 different schemes. Anti-spike/RBD IgG levels were measured between 28 and 60 days after the last dose. Side effects in participants were recorded, and pharmacovigilance records were reviewed from the outpatient vaccine clinic. Mean age of the participants was 38 +/- 11 years of whom 226 (72.9%) were female, and 84 (27.1%) were male. After booster doses, increasing antibody levels were detected in all groups. Mean antibody levels were detected to be statistically lower in 3 doses of inactivated vaccines group. The side effects were no significant difference between groups. Booster dose administration with mRNA vaccines stands out as the most accurate strategy for those at risk of contracting severe COVID-19 and HCWs caring for this population.(c) 2023 Elsevier Inc. All rights reserved.

引用

页数：6

共 50 条

[1] Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Tan, C. Sabrina
Collier, Ai-ris Y.
Yu, Jingyou
Liu, Jinyan
Chandrashekar, Abishek
McMahan, Katherine
Jacob-Dolan, Catherine
He, Xuan
Roy, Vicky
Hauser, Blake M.
Munt, Jennifer E.
Mallory, Michael L.
Mattocks, Melissa
Powers, John M.
Meganck, Rita M.
Rowe, Marjorie
Hemond, Rachel
Bondzie, Esther A.
Jaegle, Kate H.
Baric, Ralph S.
Schmidt, Aaron G.
Alter, Galit
Le Gars, Mathieu
Sadoff, Jerald
Barouch, Dan H.
JAMA NETWORK OPEN, 2022, 5 (08) : E2226335
[2] Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study
Rizvi, Nayab Batool
Bibi, Maryam
Rana, Muhmmad Zeeshan
Zaffar, Sehrish
Farooq, Hassam
FRONTIERS IN IMMUNOLOGY, 2024, 15
[3] COVID-19 vaccine and side effects
Stefansdottir, Guorun
Jacobsen, Elin I.
Guomundsdottir, Hrefna
LAEKNABLADID, 2021, 107 (03): : 151 - 151
[4] Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19
Zheng, Hui
Li, Cuidan
Zheng, Xiuyu
Jiang, Hu-Dachuan
Li, Yuqing
Yao, Aihua
Li, Xiaolong
Wang, Feiyu
Liu, Wenqing
Cao, Xiang
Qi, Runjie
Chen, Li
Jin, Lairun
Zhu, Fengcai
Li, Jingxin
Chen, Fei
FRONTIERS IN IMMUNOLOGY, 2024, 15
[5] Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore
Tan, Sharon Hui Xuan
Pung, Rachael
Wang, Lin-Fa
Lye, David Chien
Ong, Benjamin
Cook, Alex R.
Tan, Kelvin Bryan
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (12): : 1181 - 1182
[6] Oral side effects of COVID-19 vaccine
A. Riad
British Dental Journal, 2021, 230 : 59 - 59
[7] Oral side effects of COVID-19 vaccine
Riad, A.
BRITISH DENTAL JOURNAL, 2021, 230 (02) : 59 - 59
[8] Homologous and Heterologous Covid-19 Booster Vaccinations
Atmar, R. L.
Lyke, K. E.
Deming, M. E.
Jackson, L. A.
Branche, A. R.
El Sahly, H. M.
Rostad, C. A.
Martin, J. M.
Johnston, C.
Rupp, R. E.
Mulligan, M. J.
Brady, R. C.
Frenck, R. W., Jr.
Backer, M.
Kottkamp, A. C.
Babu, T. M.
Rajakumar, K.
Edupuganti, S.
Dobrzynski, D.
Coler, R. N.
Posavad, C. M.
Archer, J., I
Crandon, S.
Nayak, S. U.
Szydlo, D.
Zemanek, J. A.
Islas, C. P. Dominguez
Brown, E. R.
Suthar, M. S.
McElrath, M. J.
McDermott, A. B.
Montefiori, D. C.
Eaton, A.
Neuzil, K. M.
Stephens, D. S.
Roberts, P. C.
Beigel, J. H.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (11): : 1046 - 1057
[9] Considerations in boosting COVID-19 vaccine immune responses
Krause, Philip R.
Fleming, Thomas R.
Peto, Richard
Longini, Ira M.
Figueroa, J. Peter
Sterne, Jonathan A. C.
Cravioto, Alejandro
Rees, Helen
Higgins, Julian P. T.
Boutron, Isabelle
Pan, Hongchao
Gruber, Marion F.
Arora, Narendra
Kazi, Fatema
Gaspar, Rogerio
Swaminathan, Soumya
Ryan, Michael J.
Henao-Restrepo, Ana-Maria
LANCET, 2021, 398 (10308): : 1377 - 1380
[10] Update to living systematic review on effectiveness of heterologous and homologous covid-19 vaccine regimens
Mathioudakis, A. G.
BMJ-BRITISH MEDICAL JOURNAL, 2022, 379

← 1 2 3 4 5 →